KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Depreciation and Depletion (2024 - 2026)

Bionano Genomics recorded quarterly Depreciation and Depletion of $1.0 million in Q1 2026, up 190.91% quarter-over-quarter from -$1.1 million in Q2 2025, and down 9.09% year-over-year from $1.1 million in Q1 2025.

Bionano Genomics' Depreciation and Depletion history runs 3 years deep, the most recent figure standing at $1.0 million for Q1 2026.

  • In Q1 2026, Depreciation and Depletion fell 9.09% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $6.4 million (down 1.54% YoY), while the FY2025 annual figure was $4.2 million, down 14.29% from the prior year.
  • Depreciation and Depletion came in at $1.0 million for Q1 2026 at Bionano Genomics, up from -$1.1 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $5.4 million in Q4 2024 to a low of -$1.1 million in Q2 2025.
  • A 3-year average of $1.2 million and a median of $1.0 million in 2026 frame the typical range for Depreciation and Depletion.
  • Across the five-year window, Depreciation and Depletion jumped 320.0% in 2025 and slipped 9.09% in 2026, its largest moves.
  • Bionano Genomics' Depreciation and Depletion stood at $5.4 million in 2024, then tumbled by 120.37% to -$1.1 million in 2025, then jumped by 190.91% to $1.0 million in 2026.
  • According to Business Quant data, Depreciation and Depletion over the past three periods registered $1.0 million, -$1.1 million, and $1.1 million for Q1 2026, Q2 2025, and Q1 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn -
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn -
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn -
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 44.60 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 38.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 47.60 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 15.60 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 91.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 64.31 Mn
10 Bionano Genomics 14.92 Mn 539,417.67 3.25 Mn 1.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.00 Mn
Mar 31, 2026 1.00 Mn
Jun 30, 2025 -1.10 Mn
Jun 30, 2025 -1.10 Mn
Mar 31, 2025 1.10 Mn
Mar 31, 2025 1.10 Mn
Dec 31, 2024 5.40 Mn
Dec 31, 2024 5.40 Mn
Mar 31, 2024 -500,000.00
Mar 31, 2024 -500,000.00